CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

In trading on Friday, shares of CRISPR Therapeutics AG (Symbol: CRSP) crossed above their 200 day moving average of $49.55, changing hands as high as $52.60 per share. CRISPR Therapeutics AG ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

Vertex teamed up with CRISPR Therapeutics (NASDAQ: CRSP) on the powerful gene-editing therapy that effectively cures both rare blood disorders. The commercial ramp-up for Casgevy is taking some ...

CRISPR Therapeutics CRSP reported fourth-quarter 2024 loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.15. In the year-ago period, the company recorded ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other firms that soared on Friday. Wall Street finished mixed anew on Friday, as investors ...

StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) to a sell rating in a research report released on Thursday. Other analysts have also issued reports about the stock.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” ...